{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:26:45Z","timestamp":1780640805708,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"am","delay-in-days":321,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA206444"],"award-info":[{"award-number":["R01 CA206444"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA221813"],"award-info":[{"award-number":["R01 CA221813"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA247471"],"award-info":[{"award-number":["R01 CA247471"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA254036"],"award-info":[{"award-number":["R01 CA254036"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 HL158951"],"award-info":[{"award-number":["R01 HL158951"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["P01 CA217798"],"award-info":[{"award-number":["P01 CA217798"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["R01 CA210637"],"award-info":[{"award-number":["R01 CA210637"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["R01 CA228524"],"award-info":[{"award-number":["R01 CA228524"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["R01CA256973"],"award-info":[{"award-number":["R01CA256973"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["R01CA263575"],"award-info":[{"award-number":["R01CA263575"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["R01CA273349"],"award-info":[{"award-number":["R01CA273349"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["U01 CA200466"],"award-info":[{"award-number":["U01 CA200466"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006518","name":"University of Nebraska Medical Center","doi-asserted-by":"publisher","award":["U01 CA210240"],"award-info":[{"award-number":["U01 CA210240"]}],"id":[{"id":"10.13039\/100006518","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.canlet.2022.215922","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T11:21:31Z","timestamp":1663586491000},"page":"215922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Small molecule inhibitor against onco-mucins disrupts Src\/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"551","author":[{"given":"Chunmeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita","family":"Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palanisamy","family":"Nallasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Parte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Rauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Krishna","family":"Nimmakayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanakumar","family":"Marimuthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakanth","family":"Chirravuri-Venkata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushanta","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh C.","family":"Kukreja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthasarathy","family":"Seshacharyulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moorthy P.","family":"Ponnusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surinder K.","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.215922_bib1","unstructured":"SEER Cancer Stat Facts: Pancreatic Cancer."},{"key":"10.1016\/j.canlet.2022.215922_bib2","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 Months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2022.215922_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","article-title":"Effect of Selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial","volume":"3","author":"Chung","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2022.215922_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(17)30084-0","article-title":"Vandetanib plus Gemcitabine versus placebo plus Gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial","volume":"18","author":"Middleton","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2022.215922_bib5","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215922_bib6","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1158\/0008-5472.CAN-08-3135","article-title":"MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells","volume":"68","author":"Bafna","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib7","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1096\/fj.07-9673rev","article-title":"Structure, evolution, and biology of the MUC4 mucin","volume":"22","author":"Chaturvedi","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.canlet.2022.215922_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1078-0432.CCR-10-1937","article-title":"Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer","volume":"17","author":"Senapati","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.bjc.6605285","article-title":"Pancreatic cancer cells resistance to Gemcitabine: the role of MUC4 mucin","volume":"101","author":"Bafna","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215922_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2010.02.015","article-title":"MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem\/progenitor cells and their progenies","volume":"295","author":"Mimeault","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2022.215922_bib11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1158\/0008-5472.CAN-03-2636","article-title":"Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis","volume":"64","author":"Singh","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1541-7786.MCR-06-0353","article-title":"MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins","volume":"5","author":"Chaturvedi","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib13","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/onc.2012.179","article-title":"The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family","volume":"32","author":"Skrypek","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/0008-5472.CAN-07-6041","article-title":"MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells","volume":"68","author":"Chaturvedi","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/sj.bjc.6604517","article-title":"MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells","volume":"99","author":"Ponnusamy","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2022.215922_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14728222.2017.1323880","article-title":"MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma","volume":"21","author":"Gautam","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2022.215922_bib17","doi-asserted-by":"crossref","first-page":"30923","DOI":"10.1074\/jbc.M104204200","article-title":"Characterization of human mucin gene MUC4 promoter: importance of growth factors and proinflammatory cytokines for its regulation in pancreatic cancer cells","volume":"276","author":"Perrais","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2022.215922_bib18","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1038\/onc.2014.409","article-title":"NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer","volume":"34","author":"Kumar","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2021.01.015","article-title":"MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans","volume":"503","author":"Sagar","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2022.215922_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13123059","article-title":"Understanding the clinical impact of MUC5AC expression on pancreatic ductal adenocarcinoma","volume":"13","author":"Manne","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2022.215922_bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/carcin\/bgy019","article-title":"Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view","volume":"39","author":"Krishn","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2022.215922_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41388-020-01564-w","article-title":"Selective inhibition of stemness through EGFR\/FOXA2\/SOX9 axis reduces pancreatic cancer metastasis","volume":"40","author":"Kaushik","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103772","article-title":"Disruption of FDPS\/Rac 1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling","volume":"75","author":"Seshacharyulu","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2022.215922_bib24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/stem.2852","article-title":"Concise review: current status of three-dimensional organoids as preclinical models","volume":"36","author":"Kaushik","year":"2018","journal-title":"Stem Cell."},{"key":"10.1016\/j.canlet.2022.215922_bib25","article-title":"Recent advances in organoid development and applications in disease modeling","volume":"1875","author":"Rauth","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2022.215922_bib26","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2020.07.053","article-title":"RNA polymerase II-associated factor 1 regulates stem cell features of pancreatic cancer cells, independently of the PAF1 complex, via interactions with PHF5A and DDX3","volume":"159","author":"Karmakar","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2022.215922_bib27","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1586\/ehm.09.42","article-title":"Bosutinib: a dual SRC\/ABL kinase inhibitor for the treatment of chronic myeloid leukemia","volume":"2","author":"Keller","year":"2009","journal-title":"Expet Rev. Hematol."},{"key":"10.1016\/j.canlet.2022.215922_bib28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus Gemcitabine compared with Gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2022.215922_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2022.215922_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1515\/tjb-2017-0095","article-title":"A Src\/Abl kinase inhibitor, bosutinib, downregulates and inhibits PARP enzyme and sensitizes cells to the DNA damaging agents","volume":"43","author":"Kirmizibayrak","year":"2018","journal-title":"Turk. J. Biochem."},{"key":"10.1016\/j.canlet.2022.215922_bib31","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nchembio.1085","article-title":"Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML","volume":"8","author":"Winter","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.canlet.2022.215922_bib32","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/onc.2011.505","article-title":"Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells","volume":"31","author":"Senapati","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.canlet.2022.215922_bib34","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/onc.2010.459","article-title":"GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin","volume":"30","author":"Inaguma","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1756-9966-29-53","article-title":"RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells","volume":"29","author":"Yamazoe","year":"2010","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.215922_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-08-0126","article-title":"SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells","volume":"7","author":"Vultur","year":"2008","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2022.215922_bib37","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/onc.2013.23","article-title":"WNT7B mediates autocrine Wnt\/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma","volume":"33","author":"Arensman","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2022.215922_bib38","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1002\/cam4.3819","article-title":"Fzd7\/Wnt7b signaling contributes to stemness and chemoresistance in pancreatic cancer","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2022.215922_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103327","article-title":"A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial","volume":"66","author":"Hoyer","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2022.215922_bib40","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2014.04.008","article-title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","volume":"50","author":"Renouf","year":"2014","journal-title":"Eur. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522004098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522004098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:05:41Z","timestamp":1759593941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522004098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S0304383522004098"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215922","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule inhibitor against onco-mucins disrupts Src\/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.215922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"215922"}}